IPO closes on 27 Mar'26
Sai Parenteral Ltd
Minimum Investment
₹ 14,896 / 38 shares
Our Verdict:
Avoid
- Sai Parenteral’s Ltd (SPL) has delivered robust revenue and earnings growth over the past three years, supported by steady margin expansion.
- However, in terms of valuation, the IPO is aggressively priced at ~72x FY25 earnings, implying a meaningful premium to industry peers. Comparable companies such as Innova Captab and Gland Pharma trade at lower valuations despite having significantly larger scale and stronger earnings visibility.
- While the underlying business fundamentals and growth trajectory remain healthy, the current valuation appears stretched for a company of this size.
- Additionally, the broader market environment remains cautious, with geopolitical tensions in the Middle East weighing on investor sentiment and capital flows. Historically, IPOs launched during such periods tend to witness subdued listing performance.
- Considering the elevated valuation and uncertain macro backdrop, the risk-reward appears unfavourable at current levels. Investors may consider avoiding this IPO for now and look for better opportunities within the pharma sector at more reasonable valuations.
About the company
Founded in
12 Jan'01
Managing director
Anil Karusala
- SPL is a diversified pharmaceutical formulations company with strong capabilities across research, development and manufacturing. The business operates through two key segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services. In H1FY26, the former contributed ~72% of revenue, while CDMO accounted for ~28%.
- The company operates 5 manufacturing facilities in India and has built a broad, well-diversified product portfolio across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics and dermatology.
- Its offerings span a wide range of dosage forms such as injectables, tablets, capsules, liquid orals and topical formulations, enabling it to cater to diverse patient needs and market segments.
STRENGTHS
- Solid Track Record: SPL has demonstrated robust financial performance, with revenue growing at a CAGR of 30% between FY23 and FY25. EBITDA and net profit have grown at higher CAGRs of 50% and 82%, respectively.
- Improving Profitability: Margins have expanded steadily, with EBITDA margin increasing from 18.22% in FY23 to 24.18% in FY25. Net profit margin has also improved from 4.52% to 8.88% over the same period.
- Healthy Return Ratios: SPL exhibits strong capital efficiency, with Return on Net Worth (RoNW) at 15.09% and Return on Capital Employed (RoCE) at 28.92% in FY25.
- Diversified Product Mix: The sharp reduction in dependence on injectables—from 92% in FY23 to 26% in H1FY26—highlights a successful shift towards a more balanced and diversified portfolio, reducing concentration risk.
RISK FACTORS
- Customer Concentration: A significant portion of revenue is derived from a limited set of clients. In H1FY26, the top five customers contributed 52.65% of revenue in the Branded Generic Formulations segment and 27.75% in the CDMO segment.
- Weak Operating Cash Flows: SPL has reported negative operating cash flows in FY23, FY24 and H1FY26. Persistent negative cash generation could strain liquidity, impact day-to-day operations and limit financial flexibility.
- Regulatory Risks: SPL and its material subsidiary are involved in regulatory proceedings related to alleged manufacture or sale of sub-standard products. Any adverse outcome could lead to penalties and reputational impact.
- Execution Risk: SPL’s recent acquisition of a 74.64% stake in Noumed Pharmaceuticals Pty Ltd (Australia) introduces integration and execution risks. Inability to effectively manage international operations may impact growth, profitability and cash flows.
Financials
All Values are in Cr.
Issue details
Issue type
Mainstream
Issue size
₹ 409 crore
Fresh Issue
₹ 285 crore
OFS
₹ 124 crore
Price range
₹ 372 - 392
Lot size
38 shares
Issue Objective
The net proceeds from the issue are proposed to be utilised for the following purposes:
- Capacity expansion and upgradation of existing manufacturing facilities;
- Establishment of a new R&D centre;
- Prepayment or repayment of certain outstanding borrowings;
- Funding working capital requirements;
- Investment in its wholly-owned subsidiary in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Ltd (Australia); and
- General corporate purposes.
Dates
Bidding open
24 Mar'26
Bidding close
27 Mar'26
Allotment date
30 Mar'26
Refund date
1 Apr'26
Listing
2 Apr'26
IPO Reservations
Qualified institutional buyers
<50%
Non-institutional investors
>15%
Retail individual investors
>35%
Read the Offer Document
© 2026 by Liquide Solutions Private Limited, SEBI Registered Research Analyst (Registration number - INH000009816)
This document has been issued by Liquide Solutions Private Limited for information purposes only. It does not have regard to specific investment objectives, financial situation and the particular needs of any specific person who may receive this document. Investors should seek personal and independent advice regarding the appropriateness of investing in any of the funds, securities, other investment or investment strategies that may have been discussed or referred herein and should understand that the views regarding future prospects may or may not be realized. In no event shall Liquide Life Private Limited and / or its affiliates or any of their directors, trustees, officers and employees be liable for any direct, indirect, special, incidental or consequential damages arising out of the use of information / opinion herein.